Vancouver, Canada (Jan 6, 2012) – Xenon Pharmaceuticals Inc. (Xenon) authors publish new articles in Pain and Current Pharmaceutical Biotechnology. See PubMed for abstracts and links to full text.
Treatment of NaV1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker.
Targeting voltage-gated sodium channels for treating neuropathic and inflammatory pain